GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • *China shares hit seven-year high on ambitious Silk Road project. Also Monday, Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for $3.5 billion, and Ireland's Horizon Pharma Plc agreed to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion. Earlier, China unveiled details of an...

  • Merger Monday is back: What to buy Monday, 30 Mar 2015 | 11:44 AM ET

    This year is on track to surpass the record set in 2014 for M&A. "Merger Monday" is back. Here's how to trade it.

  • Teva buying Auspex for $3.2 billion Monday, 30 Mar 2015 | 7:31 AM ET

    NEW YORK— Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments. Jerusalem- based Teva said Monday that it will pay $101 per share, marking a 47 percent premium to San Diego- based Auspex's closing stock price on Friday.

  • Teva to buy Auspex for $101/share in cash Monday, 30 Mar 2015 | 7:09 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.

  • Three trades to go before the closing bell Monday, 16 Mar 2015 | 1:58 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Teva Pharm Q4 profit, revenue meet expectations Thursday, 5 Feb 2015 | 7:38 AM ET

    TEL AVIV, Feb 5- Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year. Teva, the world's largest generic drugmaker and Israel's biggest company, earned $1.31 per diluted share excluding one-time items in the fourth quarter, compared with $1.42 a year earlier.

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • Midday movers: Teva, Outerwall, Tiffany & more Tuesday, 20 Jan 2015 | 1:16 PM ET

    Some of Tuesday's midday movers:

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

  • Drug pricing concerns? Not at Gilead Monday, 5 Jan 2015 | 10:41 AM ET
    A scientist at Gilead Sciences' laboratory in Foster City, Calif.

    Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.